BrightInsight
BrightInsight provides a regulated cloud-based digital health platform for global biopharma and medtech companies, enabling compliant patient companion apps, Software as a Medical Device (SaMD) solutions, and AI-driven therapy persistence programs deployed across 60+ countries with enterprise customers including Sanofi, CSL Behring, Roche, and AstraZeneca.
- Company typePrivate
- Founded2018
- HeadquartersSunnyvale, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What BrightInsight does
BrightInsight is a regulated digital health platform company serving global biopharma and medtech clients. Founded in 2017-2018 as a spin-off from Flex Ltd. and headquartered in San Jose, California, it operates a cloud-based platform built on Google Cloud that provides infrastructure for patient companion applications, digital patient support programs, and Software as a Medical Device (SaMD) solutions. Its platform is supported by an extensive certification stack — ISO 13485, IEC 62304, ISO/IEC 27001, HITRUST CSF, HIPAA, GDPR, CE Mark, EU MDR, MDSAP, and HDS — enabling compliant deployment across 60+ countries under a built-in Quality Management System. The platform addresses therapy discontinuation and adherence problems that cost the industry an estimated $500B+ annually, with the flagship AI-enabled Patient Persistence Solution detecting behavioral signals that precede therapy drop-off and triggering interventions at clinically meaningful moments. Adjacent solutions include the Connected Diagnostics Platform (for IVD manufacturers such as bioMérieux) and the Disease Management Solution, with customer-facing apps such as MyWay (Sanofi), Hizentra (CSL Behring), Hemgenix, myVisionTrack (Stanford Health Care), and a CE-marked Emicizumab dosing calculator.
BrightInsight monetizes through an enterprise SaaS subscription model (annual contracts) plus professional services for implementation, customization, and consulting. Pricing is quote-based and customized to scope, therapeutic area, geography, and patient population. Go-to-market is exclusively direct enterprise sales targeting senior executives at the world's top biopharma and medtech organizations — including Sanofi, Roche, AstraZeneca, CSL Behring, Novo Nordisk, UCB, Regeneron, and bioMérieux — with marketing amplified through industry events (HLTH, JPM, BIO, HIMSS), content marketing, and an executive Digital Health C-Suite Series. Distribution is anchored on the company's regulatory clearance, demonstrated clinical outcomes (79% retention at 3 months and 71% at 12 months for Hizentra versus a ~45% industry average; 80%+ retention at 12 months for myVisionTrack), and the ability to compress custom builds from 12+ months to roughly 6 months.
The company is venture-backed and private, having raised $179M+ across five disclosed rounds, including a $101M Series C in March 2021 led by General Catalyst at a $750M valuation, and a $13M strategic investment in January 2026 from existing investors to accelerate AI-enabled persistence solutions. It has been recognized on the Deloitte Technology Fast 500 for two consecutive years and as a Frost & Sullivan Global Healthcare IoT Company of the Year. Customer concentration is anchored on a handful of large multi-year pharma partnerships, but the platform is configurable across eight therapeutic areas (cardiovascular, diabetes, gene therapy, immunology, mental health/neurology, oncology/hematology, rare diseases, respiratory), and the 2026 Havas Health global agency partnership signals an effort to broaden commercial reach at the brand level.
BrightInsight firmographics
Firmographics- Name
- BrightInsight
- Legal name
- BrightInsight, Inc.
- Website
- https://brightinsight.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- BrightInsight provides a regulated cloud-based digital health platform for global biopharma and medtech companies, enabling compliant patient companion apps, Software as a Medical Device (SaMD) solutions, and AI-driven therapy persistence programs deployed across 60+ countries with enterprise customers including Sanofi, CSL Behring, Roche, and AstraZeneca.
- Ownership category
- akta.pro rank
BrightInsight industry classification
Industry- Product category
- Digital Health Platform
- SIC
- Services-Prepackaged Software (7372), Services-Health Services (8000)
- akta.pro primary industry
- Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)
- akta.pro secondary industries
- Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF), Medication Adherence & Smart Drug Delivery (Connected Inhalers, Pens, Pill Dispensers) (HLACAPAH), Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF)
Keywords
Where BrightInsight is headquartered
LocationHeadquarters
- HQ city
- Sunnyvale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BrightInsight business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Platform/SaaS Subscription: Cloud-based platform deployed as managed service with subscription pricing. Provides infrastructure for patient companion apps, digital patient support programs, and SaMD solutions across global markets.
- Professional Services: Implementation, customization, and consulting services to deploy digital health solutions on the BrightInsight Platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise Platform Subscription |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
BrightInsight product offering
Product offeringCore offering
BrightInsight provides a cloud-based regulated digital health platform for biopharma and medtech companies, offering infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries. Its AI-enabled patient persistence solution predicts and prevents therapy drop-off by detecting behavioral signals and triggering interventions, delivering pre-built regulatory compliance modules (HIPAA, GDPR, ISO 13485, IEC 62304, HITRUST, EU MDR) and configurable tools across multiple therapeutic areas.
Product overview
BrightInsight offers a unified digital health platform architecture with multiple integrated solutions. The core BrightInsight Platform provides cloud-based infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions for biopharma and medtech companies. Built upon this platform are the Patient Persistence Solution (AI-powered therapy adherence), Disease Management Solution, and Connected Diagnostics Platform (for IVD companies). The company delivers specific patient-facing products including the MyWay App (Sanofi partnership), Hizentra App (CSL Behring), Hemgenix Companion App, and myVisionTrack App (Stanford), along with the CE-marked Emicizumab Dosing Calculator. The platform operates across 60+ countries with global regulatory compliance.
Differentiator
Problem solved
Functional benefit
Brands
- BrightInsight Platform: The company's core regulated digital health IoT platform for biopharma and medtech companies
- BrightInsight Ecosystem
- Digital Disease Management Solution
- Connected Diagnostics Platform
- Patient Persistence Solution
- Digital Health C-Suite Series
- MyWay
Products and services
- BrightInsight Platform Cloud-based regulated digital health platform for biopharma and medtech companies providing infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries.
- Patient Persistence Solution AI-powered solution that predicts and prevents therapy drop-off by unifying patient experience, detecting behavioral signals preceding discontinuation, and triggering interventions at critical moments to keep patients on therapy longer.
- Connected Diagnostics Platform Digital platform for in vitro diagnostics (IVD) companies that transforms device management from reactive to proactive, featuring workflow portals, analytics dashboards, proxy agent for device-to-cloud communication, and HL7/FHIR integration middleware.
- Disease Management Solution Digital solution for biopharma and medtech companies that enhances patient experience and drives value for therapies and devices by supporting the patient journey across care settings.
- MyWay App Software as Medical Device mobile application providing symptom tracking, medication management, and direct communication with healthcare providers for patients on Sanofi's specialty care medicines.
- Hizentra App Patient companion app for CSL Behring supporting patients taking Hizentra with medication reminders, record management, infusion tracking, and nurse educator program access; deployed in U.S., Japan, Canada, Chile, and Argentina.
- Patient App (Sanofi) Digital app developed with Sanofi and Regeneron supporting patients on biologic therapies, demonstrating 4% lower discontinuation rate and improved adherence after one year; adopted by more than 25,000 patients.
- Hemgenix Companion App Companion application developed in partnership with CSL for Hemgenix gene therapy to support patients undergoing treatment.
- Emicizumab Dosing Calculator CE-marked dosing calculator for Emicizumab, a regulated digital health solution built on the BrightInsight Platform.
- myVisionTrack App Mobile application for macular disease patients developed with Stanford Health Care, showing 80%+ patient retention at 12 months with 83% registered retinal patient engagement.
- Data & Insights Solution Solution component providing real-world data capture and actionable insights to help biopharma companies improve patient care and drive measurable business value.
- Software as a Medical Device (SaMD) Solutions Comprehensive offering for developing, launching, and scaling Software as a Medical Device products including algorithms and clinical decision support tools.
Quantifiable outcome
- 4% lower discontinuation rate and 4% improvement in adherence after one year for Sanofi Patient App users vs. non-users
- +5 more outcomes
Companies that use BrightInsight
Customer profileNamed customers9 records
Segments2 records
Ideal customer profiles3 records
BrightInsight technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
BrightInsight partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered flagship and core.
- Havas HealthflagshipExclusive global strategic partnership designating Havas Health as BrightInsight's single global agency partner for digital patient persistence and adherence solutions. Merges Havas Health's healthcare strategy and patient journey expertise with BrightInsight's compliant digital health platform. Addresses estimated $500B+ annual cost of poor patient adherence.
- SanofiflagshipExpanded multi-year partnership (initial 2022) to develop companion applications for Sanofi's specialty care medicines including MyWay mobile app and Patient App for biologic therapies. Demonstrated 4% reduction in discontinuation and 4% adherence improvement. Expansion across international markets and specialty care portfolio.
- Google CloudcoreExpanded partnership to enhance patient journey through generative AI. Long-standing technology partner since 2018 launch on Google Cloud Platform. 2018 and 2019 Google Cloud Partner of the Year for Healthcare and Life Sciences.
- bioMérieuxcorePartnership to launch clinical digital solutions for diagnostics. Connected Diagnostics Platform for clinical decision support.
- UCBcorePartnership to build digital care solutions for rare diseases leveraging BrightInsight Platform for compliant digital health solutions.
- AstraZenecacoreGlobal digital health partnership for chronic disease management. BrightInsight IoT platform selected to build and manage digital health solutions within regulatory-compliant environment.
- Novo NordiskcoreConnected insulin pens and digital diabetes management solutions using BrightInsight Platform. Long-standing partnership dating to Flex-era origins.
- RegeneronflagshipCollaboration with Sanofi on Patient App for key biologic therapy. BrightInsight developed the digital solution supporting patients on therapy with measurable adherence and persistence outcomes.
- CSL BehringflagshipEnterprise agreement for digital health solutions across brand portfolio. Hizentra app with 25%+ adoption rate, 79% retention at 3 months. Global expansion to Latin America and Canada. Hemgenix companion app for gene therapy.
- RochecoreDigital health initiatives within Roche Personalized Healthcare Division.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
BrightInsight competitors and assessment
Company assessmentBroad incumbents
- Salesforce Health Cloud: Salesforce Health Cloud is a broad CRM/patient engagement platform that biopharma and medtech customers can use for patient companion apps; a broader incumbent that competes for the same enterprise buyer.
- IQVIA: IQVIA's eCOA, Patient Cloud and decentralized trial offerings target the same biopharma/medtech buyers with regulated patient-engagement and data-capture software, but as part of a much larger CRO and analytics portfolio.
- Medidata (Dassault Systèmes): Medidata's Rave eCOA and decentralized clinical trial platform address pharma patient engagement and SaMD-adjacent use cases; competes for the same enterprise budget lines at top biopharma.
Direct peers
- Veeva Systems: Veeva Vault is the dominant regulated SaaS platform for life sciences, including patient engagement and clinical operations. Veeva is the most direct functional comparable to BrightInsight's regulated platform model serving biopharma.
- Medable: Medable provides a regulated, decentralized clinical trial and eCOA platform for biopharma — direct overlap with BrightInsight's SaMD and patient companion app capabilities for clinical and commercial use.
- Science 37: Science 37 operates a decentralized clinical trial platform with connected patient apps and remote data capture, competing for the same biopharma digital engagement and SaMD deployments.
Emerging players
- Castor: Castor offers a regulated eClinical and connected device data platform for clinical trials — overlapping with BrightInsight's Connected Diagnostics and SaMD modules but at smaller scale and primarily trial-focused.
- ObvioHealth: ObvioHealth provides a decentralized trial and patient engagement app platform aimed at biopharma sponsors, with partial overlap on patient companion apps and adherence.
Others
- Datavant: Datavant focuses on health-data connectivity and real-world data — adjacent to BrightInsight's Data & Insights module — and could be a partner or competitor in the biopharma RWE layer.
- Redox: Redox provides healthcare interoperability APIs; BrightInsight already integrates with HL7/FHIR and partners with Redox-style vendors, making it a comparable ecosystem/data-exchange peer.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BrightInsight social profiles
Digital presenceBrightInsight compliance and trust
Trust signalCompliance12 records
BrightInsight financial estimates
Financial estimateRevenue estimate
Valuation estimate
BrightInsight leadership team
Management profileNumber of profiles
Profiles8 records
BrightInsight funding detail
Funding detailFunding overview
Funding rounds4 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BrightInsight M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BrightInsight
What does BrightInsight do?
BrightInsight provides a cloud-based regulated digital health platform for biopharma and medtech companies, offering infrastructure for patient companion apps, digital patient support programs, and Software as a Medical Device (SaMD) solutions across 60+ countries. Its AI-enabled patient persistence solution predicts and prevents therapy drop-off by detecting behavioral signals and triggering interventions, delivering pre-built regulatory compliance modules (HIPAA, GDPR, ISO 13485, IEC 62304, HITRUST, EU MDR) and configurable tools across multiple therapeutic areas.
Is BrightInsight a public or private company?
BrightInsight is a private company. It is classified as venture growth investor backed and is currently operating.
When was BrightInsight founded?
BrightInsight was founded in 2018. It employs 101 to 250 people.
Where is BrightInsight based?
BrightInsight is headquartered in Sunnyvale, United States, in the North America region.
How does BrightInsight make money?
Two revenue lines are on record. Platform/SaaS Subscription is the primary driver. The others are professional Services.
Who are BrightInsight's main competitors?
Broad incumbents on record are Salesforce Health Cloud, IQVIA and Medidata (Dassault Systèmes). Direct peers are Veeva Systems, Medable and Science 37. Emerging players are Castor and ObvioHealth. Others are Datavant and Redox.
Does BrightInsight have an API?
No public API is recorded for BrightInsight.
What industry is BrightInsight in?
BrightInsight's product category is Digital Health Platform. Its primary akta.pro industry code is HLACANAH, Therapeutic Companion Apps (Drug-Device-Digital Combination), with a secondary code of HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs). Its SIC code is 7372.